---
document_datetime: 2023-10-31 11:11:20
document_pages: 2
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps/invirase-epar-procedural-steps-taken-authorisation_en.pdf
document_name: invirase-epar-procedural-steps-taken-authorisation_en.pdf
version: success
processing_time: 0.5213637
conversion_datetime: 2025-12-27 09:05:03.241878
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## BACKGROUND INFORMATION ON THE PROCEDURE

1. Submission of the dossier The  company  Roche  Registration  Limited  submitted  on  15  September  1995  an  application  for Marketing Authorisation to the European Agency for the Evaluation of Medicinal Products (EMEA) for Invirase (saquinavir) 200 mg hard capsules through the centralised procedure. After agreement by the CPMP on 11 July 1995, this medicinal product is referred to Part B of the Annex of the Council Regulation (EEC) No 2309/93 of the 22 July 1993; indent 7 as it contains a new active substance. The Rapporteur and the Co-Rapporteur appointed by the CPMP were: Rapporteur: Dr. H. Pittner Co-Rapporteur: Prof. K. Strandberg Licensing status: Invirase has been approved in several countries including the USA, Switzerland, Canada and Australia. 2. Steps taken for the assessment of the product · An application for marketing authorisation for Invirase was submitted to the EMEA on 15 September 1995. The centralised procedure started on 2 October 1995. · During the December CPMP Meeting 1995, it was agreed to perform a GMP inspection on the Switzerland manufacturing facility for the finished medicinal product by the  German inspectorates. The inspection took place on 12-14 February 1996. · The Co-Rapporteur's assessment report was circulated to all CPMP Members on 15 December 1995. The Rapporteur's assessment report was circulated to all CPMP Members on 18 December 1995. · A breakout session between Rapporteur and Co-Rapporteur evaluation teams was held on 2 February 1996 to prepare a draft consolidated list of questions. · The consolidated list of questions as agreed by the CPMP on 14 February 1996, was sent to the applicant. · The joint Rapporteur and Co-Rapporteur assessment report on the responses on the consolidated list of questions was circulated to all CPMP Members on 28 May 1996. · An  extended  assessment  report  of  the  clinical  study  NV14256  was  circulated  to  all  CPMP Members by the Co-Rapporteur on 31 May 1996 and the Rapporteur on 3 June 1996. · A  hearing  with  the  applicant  was  held  on  18  June  1996  during  the  June  CPMP  meeting  to address the strategy of ongoing clinical studies with particular emphasis on those studies, which are intended to new pharmaceutical forms and new dosage regimens. · The applicant submitted on 19 June 1996 their letter of commitments for providing information on  clinical  aspects  (submission  of  final  reports  of  the  ongoing  clinical  studies  NV14256  and 14604) as part of the re-assessment of the benefit/risk profile. The applicant also committed it to provide additional data regarding quality, safety and efficacy aspects. Medicinal product no longer authorised

<!-- image -->

- The  CPMP in  the  light  of  the  overall  data  submitted  and  the  scientific  discussion  within  the Committee issued on 20 June 1996 a positive opinion for granting a Marketing Authorisation for Invirase under exceptional circumstances.
- Following  a  rapid  alert  from  France  on  the  14  June  1996  drawing  attention  to  reports  of spontaneous  bleedings  in  haemophiliac  patients  involved  in  the  'Autorisation  Temporaire d'Utilisation (ATU)' programme, the CPMP during their meeting of 16-17 July 1996 agreed to revise  the  opinions  adopted  on  19  June  1996.  In  the  revised  opinions,  warnings  have  been

<div style=\"page-break-after: always\"></div>

introduced into the Summary of Product Characteristics and in the Package Leaflet in the light of the information available.

<!-- image -->

· The wordings proposed by the CPMP were discussed between the Chairman of the Committee and  the  companies  involved  in  the  marketing  of  protease  inhibitors.  An  agreement  on  the warnings to be introduced was reached on Monday 22 July 1996. · The CPMP revised opinion was forwarded, in all official languages of the European Union, to the European Commission, which adopted the corresponding Decision on 4 October 1996. Medicinal product no longer authorised